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Between 2000 and 2004, dengue virus type 1 (DENV-1) genotypes I and II from Asia were
introduced into the Pacific region and co-circulated in some localities. Envelope protein gene
sequences of DENV-1 from 12 patients infected on the island of New Caledonia were obtained,
five of which carried genotype I viruses and six, genotype II viruses. One patient harboured a
mixed infection, containing viruses assigned to both genotypes I and II, as well as a number of
inter-genotypic recombinants. This is the first report of a population of dengue viruses isolated
from a patient containing both parental and recombinant viruses.
Dengue is a major cause of mortality and morbidity in the
tropics (Gubler & Meltzer, 1999), and the ability of
positive-sense RNA viruses, such as dengue virus (DENV),
to evolve rapidly (Craig et al., 2003; Sittisombut et al.,
1997; Thu et al., 2004; Wang et al., 2002; Wittke et al.,
2002) poses a serious challenge to the development and
efficacy of vaccines. The principal source of the genetic
diversity in DENV is error-prone replication with RNA-
dependent RNA polymerase (Steinhauer et al., 1992), such
that one genomic mutation occurs in nearly every cycle of
virus replication. DENV populations at a particular locality
may also change rapidly due to periodic selective sweeps
(Bennett et al., 2003), to the introduction of exotic strains
of virus (A-Nuegoonpipat et al., 2004; Messer et al., 2003;
Rico Hesse et al., 1997; Thu et al., 2004), to random genetic
bottlenecks (Sittisombut et al., 1997; Thu et al., 2004;
Wittke et al., 2002) or to intra-serotypic recombination
(AbuBakar et al., 2002; Domingo et al., 2006; Holmes et al.,
1999; Tolou et al., 2001; Worobey et al., 1999). Whilst it is
widely accepted that another positive-strand RNA virus,
polio virus, undergoes both intra-serotypic (Ledinko,
1963) and inter-serotypic (Minor et al., 1986; Tolskaya
et al., 1983) recombination, as well as inter-species
recombination (Kew et al., 2002), there has been
considerable debate about whether recombination occurs
in DENV (Rico-Hesse, 2003) and the relevance of any
recombination to the deployment of live-attenuated
flavivirus vaccines (Monath et al., 2005; Seligman &
Gould, 2004). However, there is no mechanistic reason
why recombination cannot occur in DENV and this
process is being described with increasing frequency in
hepatitis C virus, another member of the family
Flaviviridae (Bernardin et al., 2006; Gao et al., 2007;
Kageyama et al., 2006; Legrand-Abravanel et al., 2007;
Moreno et al., 2006; Noppornpanth et al., 2006).
The ecological conditions most likely to facilitate recomb-
ination in DENV involve the co-circulation of multiple viral
populations, including distinct genotypes, so that there are
opportunities for a mosquito vector to ingest multiple
variants by feeding on a number of infected hosts, or for a
host to be infected almostsimultaneously by vectors infected
with different viruses. These opportunities exist throughout
most of south-east Asia. Further, as there are numerous
reportsofmultipleserotypesofDENVrecoveredfromsingle
hosts (Gubler et al., 1985; Laille et al., 1991; Twiddy et al.,
2002; Wang et al., 2003), it is likely that mixed infections
with different genotypes of the same serotype occur where
they co-circulate, but that current diagnostic procedures are
unable to detect such mixtures. An opportunity for frequent
mixed infections with different strains of DENV arose after
2000, when multiple genotypes of DENV-1 were introduced
into the Pacific from distant Asian localities, including
the Philippines, Myanmar/Thailand and Malaysia
(A-Nuegoonpipat et al., 2004).
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A table showing oligonucleotide primers used for PCR or sequencing of
the DENV-1 E genes, a chromatogram of the sequence of comple-
mentary-strand cDNA obtained following RT-PCR and a sequence
alignment (NEXUS format) are available as supplementary material with
the online version of this paper.
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Caledonia during an outbreak in 2002 and 2003, virus was
first recovered from 12 patients by culturing 100 ml serum
on 25 cm
2 monolayers of C6-36 Aedes albopictus cells in 7–
8 ml RPMI 1640 tissue-culture medium at 30 uC for
7 days. RNA was recovered from virus in supernate from
the infected cultures of C6-36 cells and from the serum of
patient D1.New Caledonia.416/03 by using QIAamp viral
RNA mini columns (Qiagen) according to the manufac-
turer’s instructions. The envelope (E) protein gene was
amplified by RT-PCR (A-Nuegoonpipat et al., 2004) using
oligonucleotide primers D1-764F and D1-2467R (see
Supplementary Table S1, available in JGV Online),
corresponding to regions of the pre-membrane and non-
structural 1 proteins of DENV-1, and a mixture of Taq and
Pwo polymerases (Expand Long Template DNA polymer-
ase; Roche). The PCR product was analysed on 1.5% (w/v)
agarose–Tris/acetate EDTA gels and the band of cDNA of
interest was excised and purified by using a High Pure PCR
Purification kit (Roche) according to the manufacturer’s
instructions. Approximately 100 ng cDNA or 600 ng
plasmid (see below) was sequenced, using 6.4 pmol
oligonucleotide primer and an ABI PRISM Dye
Terminator cycle sequencing ready reaction kit (Perkin
Elmer) according to the manufacturer’s instructions. The
product was purified by using Dye-EX spin columns
(Qiagen) and analysed at the Australian Genome Research
Facility on a 3730XL nucleotide sequencer (Applied
Biosystems). Sequences are identified as DENV serotype,
country of origin, sample number (and clone number)/
year sample obtained.
To determine the DENV-1 genotype of each of 12 New
Caledonian viruses, we conducted a maximum-likelihood
(ML) phylogenetic analysis of the complete E gene
(1485 bp) by using the PAUP* package (Swofford, 2003)
with the best-fit GTR+C4 model of nucleotide substi-
tution, determined by using MODELTEST (Posada &
Crandall, 1998), and 1000 bootstrap neighbour-joining
replications under the same ML model (the sequence
alignment is provided as a NEXUS file in JGV Online). This
analysis revealed that five patients were infected with
genotype I viruses, whilst six patients were infected with
viruses of genotype II (tree not shown; available from
authors on request). However, it was not possible to obtain
an unambiguous consensus nucleotide sequence, using
cDNA as a template, for the E gene of a single virus isolate
– D1.New Caledonia.416/03 – taken from a patient who
developed dengue in New Caledonia in February 2003
(chromatogram available in JGV Online as Supplementary
Fig. S1; all other isolates gave unambiguous sequences).
Therefore, cDNA corresponding to the E genes of viruses
from this patient was derived by RT-PCR using primers
D1-764F and D1-2467R or D1-938F and D1-2386R (used
to prepare clones D1.New Caledonia.416.3/03, 10/03, 14/03
and 91/03) and purified from 1.5% (w/v) agarose–Tris/
acetate EDTA gels by using a High Pure PCR purification
kit (Roche) according to the manufacturer’s instructions.
59-ATP extensions were added to the cDNA (Craig et al.,
2003) and it was ligated into pGEM-T Easy plasmids
(Promega) and used to transform Escherichia coli JM109 or
DH5a bacteria (Sambrook & Russell, 2001). Plasmids were
purified from individual bacterial colonies, which grew on
Luria–Bertani agar supplemented with 100 mg ampicillin
ml
21, 0.5 mM IPTG and 80 mg 5-bromo-4-chloro-indoyl-
b-D-galactosidase ml
21 (Sambrook & Russell, 2001), using
a commercial plasmid purification kit (Qiagen).
The nucleotide sequences of 24 clones derived from the
virus population of D1.New Caledonia.416/03 (including
seven obtained directly from serum and denoted ‘416S’ in
all figures) varied at 266 sites. Clones 19 and 32 had single-
nucleotide deletions at E250 and E308, respectively,
resulting in frame-shifts and the production of down-
stream stop codons. The deduced amino acid sequences of
the clones varied at 110 sites (after replacement of the
nucleotide deletions in the sequences of clones 19 and 32).
Clone 32 also had a stop codon (UAG) at amino acid
position E248, as did clone 7 at E391.
Notably, some sequences of the clones from patient
D1.New Caledonia.416/03 segregated with both genotype
I and genotype II DENV-1, which were circulating in New
Caledonia during the same outbreak, whereas others
occupied ‘intermediate’ phylogenetic positions between
the two genotypes, suggestive of recombination (Figs 1–3).
To determine whether recombination had occurred among
the viruses sampled from patient D1.New Caledonia.416/
03, we employed the RDP2 program (Martin et al., 2005),
which employs six different algorithms to identify
recombinants and their break points: RDP, SiScan,
BOOTSCAN, CHIMERIC, MaxChi and GENECONV. Default
settings were used in all cases. Strikingly, all six methods
identified frequent recombination events; for example,
GENECONV, which is considered one of the most robust
methods for detecting recombination (Posada, 2002),
identified 1609 possible recombination events. Among all
six methods in RDP2, there was particularly strong evidence
for recombination break points at nucleotide positions 570,
620 and 1100.
To test further for recombination, ML phylogenetic trees
were inferred for the regions of nucleotide sequence on
either side of the break points detected by RDP2 using the
methods described above (Figs 1–3). This analysis provided
compelling evidence for recombination among the geno-
type I and II viruses that co-infected patient D1.New
Caledonia.416/03, involving clones 1 (recombination event
1), 19 (recombination event 2) and 22 (recombination
event 3). For each of these three recombinants, there was
strong evidence for the phylogenetic incongruence indic-
ative of recombination; the viruses occupied different
phylogenetic (i.e. genotypic) positions on either side of
specific break points that were supported by high numbers
of bootstrap replications. Although clones 1, 19 and 22
represent clear instances of inter-genotype recombination,
the extremely high frequency of recombination identified
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http://vir.sgmjournals.org 3335Fig. 1. The changing phylogenetic position of clone D1.New Caledonia.416.1/03 (boxed), indicative of inter-genotypic
recombination in DENV-1. The maximum-likelihood phylogenetic tree was inferred by using all (n524) clones from patient
D1.New Caledonia.416/03 (in italics), as well as the consensus sequences from 11 other patients sampled from New
Caledonia, inferred for the entire E gene (1485 bp). Clones derived from serum are denoted ‘416S’. Bootstrap values are
shown for key nodes only and all branches are scaled according to the number of nucleotide substitutions per site.
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other sequences (for example, clones 18 and 32 in Fig. 3),
suggests that this process has occurred very frequently in
this patient. Crucially, none of the break points were in
regions containing sequences the same as, or complement-
ary to, the sequences of oligonucleotide primers used for
sequencing or for PCR, indicating that they are bona fide
recombinants rather than laboratory artefacts.
As less than 50 ml (badly degraded) serum was available
from patient D1.New Caledonia.416/03 after virus isolation
had been performed, only seven clones of the E protein
Fig. 2. The changing phylogenetic position of clone D1.New Caledonia.416.19/03 (boxed), indicative of inter-genotypic
recombination in DENV-1 (sequence labels as defined in the legend to Fig. 1). Bootstrap values are shown for key nodes only
and all branches are scaled according to the number of nucleotide substitutions per site.
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these clones served to confirm the presence of genotype 1
DENV-1 in this patient, but as none were recombinant, we
were unable to distinguish whether the recombinant
genomes that we detected in this virus isolate arose in
the patient or during the isolation of the virus in cultures
of A. albopictus mosquito cells. Indeed, it is highly likely
that C6-36 cells amplify some subpopulations of virus
selectively. Nonetheless, our results provide unambiguous
evidence of intra-serotypic recombination in populations
Fig. 3. The changing phylogenetic position of clone D1.New Caledonia.416.22/03 (boxed), indicative of inter-genotypic
recombination in DENV-1 (sequence labels as defined in the legend to Fig. 1). Bootstrap values are shown for key nodes only
and all branches are scaled according to the number of nucleotide substitutions per site.
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from a species of mosquito involved in dengue transmis-
sion. However, we are unable to determine whether these
recombinants are viable, as it not possible to plaque-purify
DENV to homogeneity. Even if the recombinant E protein
is functional, nucleotide insertions and deletions elsewhere
in the genome could render the virus non-functional.
This is only the second observation of both parental and
recombinant DENV in a population within a single host
(Craig et al., 2003). Whilst there are several reports of
infections of humans with multiple DENV serotypes, most
techniques employed to identify virus in patient tissues
would not detect infections with multiple genotypes of the
same DENV serotype, as is clearly necessary to give rise to
the recombinant viral populations described here. We
therefore propose that recombination events in DENV may
occur more frequently than has been reported, but that the
practice of determining consensus nucleotide sequences
from cDNA greatly limits the chances of their detection;
only if the recombinant represents the dominant viral
population will it be sampled by consensus sequencing.
Further, nucleotide deletions, which also may be the
footprints of recombination events, have been observed in
a number of DENV populations (Aaskov et al., 2006; Craig
et al., 2003; Lin et al., 2004; Wang et al., 2002). Hence, the
examination of a much larger number of recombinant
viruses and their parents may enable ‘hot spots’ of
recombination to be identified and permit a systematic
analysis of the factors mediating recombination in these
viruses (Nagy & Simon, 1997).
By continuing to monitor the epidemiology of the ongoing
outbreak of DENV-1 virus infection in the Pacific, it may
be possible to determine whether the recombination events
described here have conferred any fitness benefit on these
viruses, although it is likely that most recombinants are
deleterious and so removed by purifying selection. This
notwithstanding, it is remarkable that both parental and
different recombinant viral genomes were observed in an
isolate from a single patient, particularly as the recomb-
ination appeared to have involved two genotypes of
DENV-1 imported into New Caledonia (A-Nuegoonpipat
et al., 2004). This suggests that recombination in DENV
may be more common than thought previously, but that
the process will remain largely undetected until more
studies of clonal diversity are undertaken.
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